Cited by 1,313PI3K/AKT/mTOR signaling in cancerRNA and protein synthesis mechanismsRNA modifications and cancer

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

The translational landscape of mTOR signalling steers cancer initiation and metastasis

Open access

Hsieh, Andrew C., Liu, Yi, Edlind, Merritt P., Ingolia, Nicholas T., Janes, Matthew R., Sher, Annie, Shi, Evan Y., Stumpf, Craig R., Christensen, Carly, Bonham, Michael J., Wang, Shunyou, Ren, Pingda, Martin, Michael, Jessen, Katti, Feldman, Morris E., Weissman, Jonathan S., Shokat, Kevan M., Rommel, Christian, Ruggero, Davide·2012·Nature

DOI 10.1038/nature10912PMC PMC3663483

Open this paper in CoChat — free account

Abstract

The mammalian target of rapamycin (mTOR) kinase is a master regulator of protein synthesis that couples nutrient sensing to cell growth and cancer. However, the downstream translationally regulated nodes of gene expression that may direct cancer development are poorly characterized. Using ribosome profiling, we uncover specialized translation of the prostate cancer genome by oncogenic mTOR signalling, revealing a remarkably specific repertoire of genes involved in cell proliferation, metabolism and invasion. We extend these findings by functionally characterizing a class of translationally controlled pro-invasion messenger RNAs that we show direct prostate cancer invasion and metastasis downstream of oncogenic mTOR signalling. Furthermore, we develop a clinically relevant ATP site inhibitor of mTOR, INK128, which reprograms this gene expression signature with therapeutic benefit for prostate cancer metastasis, for which there is presently no cure. Together, these findings extend our understanding of how the 'cancerous' translation machinery steers specific cancer cell behaviours, including metastasis, and may be therapeutically targeted.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature10912

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

Vimentin Is a Novel Anti-Cancer Therapeutic Target; Insights from In Vitro and In Vivo Mice Xenograft Studies
Lahat, G., Zhu, Q., Huang, K.-L., Wang, S., Bolshakov, S. V., Liu, J., Torres, K. E., Langley, R. R., Lazar, A. J., Hung, M., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010105 · Cited by 213
Self-citation
Retracted
Genome-Wide Analysis in Vivo of Translation with Nucleotide Resolution Using Ribosome Profiling
Ingolia, N. T., Ghaemmaghami, S., Newman, J. R. S., & Weissman, J. S. (2009) · Science · doi:10.1126/science.1168978 · Cited by 3,853
Self-citation
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N. D., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E. G., Reva, B. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,713
mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery
Kim, D., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument‐Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 3,051
Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton
Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
Regulation of translation initiation by FRAP/mTOR
Gingras, A.-C., Raught, B., & Sonenberg, N. (2001) · Genes & Development · doi:10.1101/gad.887201 · Cited by 1,545
The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44
Liu, C., Kelnar, K., Liu, B., Chen, X., Calhoun‐Davis, T., Li, H., Patrawala, L., Yan, H., Jeter, C. R., Honorio, S., et al. (2011) · Nature Medicine · doi:10.1038/nm.2284 · Cited by 1,410
SIN1/MIP1 Maintains rictor-mTOR Complex Integrity and Regulates Akt Phosphorylation and Substrate Specificity
Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S. Y., Huang, Q., Qin, J., & Su, B. (2006) · Cell · doi:10.1016/j.cell.2006.08.033 · Cited by 1,407
MicroRNA-10a binds the 5’UTR of ribosomal protein mRNAs and enhances their translation
Ørom, U. A., Nielsen, F. C., & Lund, A. H. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.05.001 · Cited by 1,384
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Feldman, M. E., Apsel, B., Uotila, A., Loewith, R., Knight, Z. A., Ruggero, D., & Shokat, K. M. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000038 · Cited by 1,111
Self-citation

Flagged first, then by citations

Show all 40 references

Sorted by citations

Items 301–400 of 1,002

mTORC1 signaling activates NRF1 to increase cellular proteasome levels
Zhang, Y., & Manning, B. D. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1044188 · Cited by 85
Aberrant Proteostasis of BMAL1 Underlies Circadian Abnormalities in a Paradigmatic mTOR-opathy
Lipton, J. O., Boyle, L. M., Yuan, E. D., Hochstrasser, K. J., Chifamba, F. F., Nathan, A., Tsai, P. T., Davis, F. C., & Şahin, M. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.008 · Cited by 87
Functional Dynamics within the Human Ribosome Regulate the Rate of Active Protein Synthesis
Ferguson, A., Wang, L., Altman, R. B., Terry, D. S., Juette, M. F., Burnett, B. J., Alejo, J. L. P., Dass, R. A., Parks, M., Vincent, C. T., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.09.013 · Cited by 91
GKAP Acts as a Genetic Modulator of NMDAR Signaling to Govern Invasive Tumor Growth
Li, L., Zeng, Q., Bhutkar, A. J., Galván, J. A., Karamitopoulou, E., Noordermeer, D., Peng, M.-W., Piersigilli, A., Perren, A. A., Zlobec, I., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.011 · Cited by 84
Ribosome profiling: a Hi‐Def monitor for protein synthesis at the genome‐wide scale
Michel, A. M., & Baranov, P. V. (2013) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1172 · Cited by 86
Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies
Bumbaca, B., & Li, W. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.04.007 · Cited by 83
Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer
Wyatt, A. W., Mo, F., Wang, K., McConeghy, B., Brahmbhatt, S., Jong, L., Mitchell, D. M., Johnston, R. L., Haegert, A., Li, E., et al. (2014) · Genome Biology · doi:10.1186/s13059-014-0426-y · Cited by 82
Riborex: fast and flexible identification of differential translation from Ribo-seq data
Li, W., Wang, W., Uren, P. J., Penalva, L. O. F., & Smith, A. D. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx047 · Cited by 83
A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer
Graham, L. S., Banda, K., Torres, A., Carver, B. S., Chen, Y., Pisano, K., Shelkey, G., Curley, T., Scher, H. I., Lotan, T. L., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0578-9 · Cited by 84
Self-citation
mRNA 3′-UTR shortening is a molecular signature of mTORC1 activation
Chang, J.-W., Zhang, W., Yeh, H.-S., de Jong, E. P., Jun, S., Kim, K., Bae, S. S., Beckman, K. B., Hwang, T. H., Kim, K.-S., et al. (2015) · Nature Communications · doi:10.1038/ncomms8218 · Cited by 89
Dlx-2 and glutaminase upregulate epithelial-mesenchymal transition and glycolytic switch
Lee, S. Y., Jeon, H. M., Ju, M. K., Jeong, E. K., Kim, C. H., Park, H. G., Han, S. I., & Kang, H. S. (2016) · Oncotarget · doi:10.18632/oncotarget.6879 · Cited by 82
The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer
Turnham, D. J., Bullock, N., Dass, M. S., Staffurth, J. N., & Pearson, H. B. (2020) · Cells · doi:10.3390/cells9112342 · Cited by 85
uORFdb—a comprehensive literature database on eukaryotic uORF biology
Wethmar, K., Barbosa-Silva, A., Andrade-Navarro, M. A., & Leutz, A. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt952 · Cited by 89
Nutrient Signaling in Protein Homeostasis: An Increase in Quantity at the Expense of Quality
Conn, C. S., & Qian, S. (2013) · Science Signaling · doi:10.1126/scisignal.2003520 · Cited by 84
Milk: an epigenetic amplifier of FTO-mediated transcription? Implications for Western diseases
Melnik, B. C. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0746-z · Cited by 82
Targeted Inhibition of ULK1 Promotes Apoptosis and Suppresses Tumor Growth and Metastasis in Neuroblastoma
Dower, C. M., Bhat, N., Gebru, M. T., Chen, L., Wills, C. A., Miller, B. A., & Wang, H. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0176 · Cited by 82
mTORC1 and ferroptosis: Regulatory mechanisms and therapeutic potential
Lei, G., Zhuang, L., & Gan, B. (2021) · BioEssays · doi:10.1002/bies.202100093 · Cited by 82
A researcher’s guide to the galaxy of IRESs
Terenin, I. M., Smirnova, V. V., Andreev, D. E., Dmitriev, S. E., & Shatsky, I. N. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2409-5 · Cited by 82
mTOR and other effector kinase signals that impact T cell function and activity
Myers, D. R., Wheeler, B. D., & Roose, J. P. (2019) · Immunological Reviews · doi:10.1111/imr.12796 · Cited by 83
The molecular basis of mTORC1-regulated translation
Thoreen, C. C. (2017) · Biochemical Society Transactions · doi:10.1042/bst20160072 · Cited by 82
Controversies around the function of LARP1
Berman, A. J., Thoreen, C. C., Dedeić, Z., Chettle, J., Roux, P. P., & Blagden, S. P. (2020) · RNA Biology · doi:10.1080/15476286.2020.1733787 · Cited by 83
Integrative multi-omics approaches to explore immune cell functions: Challenges and opportunities
Wang, X., Dian, F., Yang, Y., Gimple, R. C., & Zhou, S. (2023) · iScience · doi:10.1016/j.isci.2023.106359 · Cited by 87
Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models
Gökmen‐Polar, Y., Liu, Y., Toroni, R. A., Sanders, K. L., Mehta, R. J., Badve, S., Rommel, C., & Sledge, G. W. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2298-8 · Cited by 80
Self-citation
CAMKK2 Promotes Prostate Cancer Independently of AMPK via Increased Lipogenesis
Penfold, L., Woods, A., Muckett, P. J., Nikitin, A. Y., Kent, T. R., Zhang, S., Graham, R., Pollard, A., & Carling, D. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0585 · Cited by 81
4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer
Wang, Z., Feng, X., Molinolo, A., Martı́n, D., Vitale-Cross, L. A., Nohata, N., Ando, M., Wahba, A., Amornphimoltham, P., Wu, X., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1220 · Cited by 84
Emerging Role of Eukaryote Ribosomes in Translational Control
Venezia, N. D., Vincent, A., Marcel, V., Catez, F., & Diaz, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051226 · Cited by 85
A Dynamic rRNA Ribomethylome Drives Stemness in Acute Myeloid Leukemia
Zhou, F., Aroua, N., Liu, Y., Rohde, C., Cheng, J., Wirth, A.-K., Fijałkowska, D., Göllner, S., Lotze, M., Yun, H., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0210 · Cited by 81
Self-citation
Systematic Interrogation of 3q26 Identifies TLOC1 and SKIL as Cancer Drivers
Hägerstrand, D., Tong, A., Schumacher, S. E., Ilić, N., Shen, R. R., Cheung, H. W., Vázquez, F., Shrestha, Y., Kim, S. Y., Giacomelli, A. O., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0592 · Cited by 78
The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer
Rebello, R. J., Kusnadi, E. P., Cameron, D. P., Pearson, H. B., Lesmana, A., Devlin, J. R., Drygin, D., Clark, A. K., Porter, L. H., Pedersen, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0124 · Cited by 79
MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma
Zhan, Y., Guo, J., Yang, W., Gonçalves, C., Rzymski, T., Dreas, A., Żyłkiewicz, E., Mikulski, M., Brzózka, K. D., Gołas, A., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91258 · Cited by 77
Rapid Discovery and Structure–Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase
Fraser, C., Dawson, J. C., Dowling, R., Houston, D. R., Weiss, J. T., Munro, A. F., Muir, M., Harrington, L. A., Webster, S. P., Frame, M. C., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00065 · Cited by 77
Drug discovery targeting the mTOR pathway
Martelli, A. M., Buontempo, F., & McCubrey, J. A. (2018) · Clinical Science · doi:10.1042/cs20171158 · Cited by 77
The mTORC1/4E-BP pathway coordinates hemoglobin production with L -leucine availability
Chung, J., Bauer, D. E., Ghamari, A., Nizzi, C. P., Deck, K. M., Kingsley, P. D., Yien, Y. Y., Huston, N. C., Chen, C., Schultz, I. J., et al. (2015) · Science Signaling · doi:10.1126/scisignal.aaa5903 · Cited by 84
Persistent androgen receptor addiction in castration-resistant prostate cancer
Schweizer, M. T., & Yu, E. Y. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0225-2 · Cited by 77
AR-Signaling in Human Malignancies: Prostate Cancer and Beyond
Schweizer, M. T., & Yu, E. Y. (2017) · Cancers · doi:10.3390/cancers9010007 · Cited by 75
Translation initiation factors and their relevance in cancer
de la Parra, C., Walters, B., Geter, P. A., & Schneider, R. J. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.11.001 · Cited by 75
LARP1 on TOP of ribosome production
Fonseca, B. D., Lahr, R. M., Damgaard, C. K., Alain, T., & Berman, A. J. (2018) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1480 · Cited by 79
Accurate detection of short and long active ORFs using Ribo-seq data
Choudhary, S., Li, W., & Smith, A. D. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz878 · Cited by 76
Suppression of Ribosomal Pausing by eIF5A Is Necessary to Maintain the Fidelity of Start Codon Selection
Manjunath, H., Zhang, H., Rehfeld, F., Han, J., Chang, T.-C., & Mendell, J. T. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.129 · Cited by 75
Dysregulated Ribosome Biogenesis Reveals Therapeutic Liabilities in Cancer
Bursać, S., Prodan, Y., Pullen, N., Bártek, J., & Volarević, S. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.08.003 · Cited by 74
The butterfly effect in cancer: A single base mutation can remodel the cell
Hart, J. R., Zhang, Y., Liao, L., Ueno, L. A., Du, L., Jonkers, M., Yates, J. R., & Vogt, P. K. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424012112 · Cited by 74
First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models
Pairawan, S., Zhao, M., Yuca, E., Annis, A., Evans, K., Sutton, D., Carvajal, L., Ren, J.-G., Santiago, S., Guerlavais, V., et al. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01406-x · Cited by 73
Targeting L-type amino acid transporter 1 for anticancer therapy: clinical impact from diagnostics to therapeutics
Jin, S., Jin, H., & Hong, S. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2015.1044975 · Cited by 73
GOLM1 promotes prostate cancer progression through activating PI3K‐AKT‐mTOR signaling
Yan, G., Ru, Y., Wu, K., Yan, F., Wang, Q., Wang, J., Pan, T., Zhang, M., Han, H., Li, X., et al. (2017) · The Prostate · doi:10.1002/pros.23461 · Cited by 73
4E-BPs require non-canonical 4E-binding motifs and a lateral surface of eIF4E to repress translation
Igreja, C., Peter, D., Weiler, C., & Izaurralde, E. (2014) · Nature Communications · doi:10.1038/ncomms5790 · Cited by 73
Oncogenic Signalling through Mechanistic Target of Rapamycin (mTOR): A Driver of Metabolic Transformation and Cancer Progression
Rad, E., Murray, J. T., & Tee, A. R. (2018) · Cancers · doi:10.3390/cancers10010005 · Cited by 73
The Target of Rapamycin and Mechanisms of Cell Growth
Tee, A. R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030880 · Cited by 75
Translational control and the cancer cell response to stress
Robichaud, N., & Sonenberg, N. (2017) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2017.05.007 · Cited by 73
A rare codon-based translational program of cell proliferation
Guimaraes, J. C., Mittal, N., Gnann, A., Jedlinski, D., Riba, A., Buczak, K., Schmidt, A., & Zavolan, M. (2020) · Genome biology · doi:10.1186/s13059-020-1943-5 · Cited by 73
A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma
Horvilleur, E., Sbarrato, T., Hill, K., Spriggs, R. V., Screen, M., Goodrem, P. J., Sawicka, K., Chaplin, L. C., Touriol, C., Packham, G., et al. (2013) · Leukemia · doi:10.1038/leu.2013.295 · Cited by 76
Quantitative profiling of caspase-cleaved substrates reveals different drug-induced and cell-type patterns in apoptosis
Shimbo, K., Hsu, G. W., Nguyen, H. C. X., Mahrus, S., Trinidad, J. C., Burlingame, A. L., & Wells, J. A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208616109 · Cited by 72
Enhanced translation expands the endo-lysosome size and promotes antigen presentation during phagocyte activation
Hipolito, V. E. B., Diaz, J. A., Tandoc, K. V., Oertlin, C., Ristau, J., Chauhan, N., Sarić, A., McLaughlan, S., Larsson, O. S., Topisirović, I., et al. (2019) · PLoS Biology · doi:10.1371/journal.pbio.3000535 · Cited by 73
Widespread Alterations in Translation Elongation in the Brain of Juvenile Fmr1 Knockout Mice
Sharma, S. D., Metz, J. B., Li, H., Hobson, B. D., Hornstein, N. J., Sulzer, D., Tang, G., & Sims, P. A. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.02.086 · Cited by 71
Assessing gene-level translational control from ribosome profiling
Olshen, A. B., Hsieh, A. C., Stumpf, C. R., Olshen, R. A., Ruggero, D., & Taylor, B. S. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt533 · Cited by 73
Self-citation
N6-methyladenosine mRNA marking promotes selective translation of regulons required for human erythropoiesis
Kuppers, D. A., Arora, S., Lim, Y., Lim, A. R., Carter, L. M., Corrin, P. D., Plaisier, C. L., Basom, R., Delrow, J. J., Wang, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12518-6 · Cited by 74
Self-citation
Control of the eIF4E activity: structural insights and pharmacological implications
Romagnoli, A., D’Agostino, M., Ardiccioni, C., Maracci, C., Motta, S., Teana, A. L., & Marino, D. D. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03938-z · Cited by 74
mTOR Kinase: A Possible Pharmacological Target in the Management of Chronic Pain
Lisi, L., Aceto, P., Navarra, P., & Russo, C. D. (2015) · BioMed Research International · doi:10.1155/2015/394257 · Cited by 71
The 4E-BP–eIF4E axis promotes rapamycin-sensitive growth and proliferation in lymphocytes
So, L., Lee, J., Palafox, M., Mallya, S., Woxland, C. G., Arguello, M., Truitt, M., Sonenberg, N., Ruggero, D., & Fruman, D. A. (2016) · Science Signaling · doi:10.1126/scisignal.aad8463 · Cited by 72
Self-citation
The lysosomal TRPML1 channel regulates triple negative breast cancer development by promoting mTORC1 and purinergic signaling pathways
Xu, M., Almasi, S., Yang, Y., Yan, C. W., Sterea, A. M., Syeda, A. K. R., Shen, B. Q., Clements, D. R., Huang, P., Gujar, S. A., et al. (2019) · Cell Calcium · doi:10.1016/j.ceca.2019.02.010 · Cited by 70
mTOR-sensitive translation: Cleared fog reveals more trees
Masvidal, L., Hulea, L., Furic, L., Topisirović, I., & Larsson, O. S. (2017) · RNA Biology · doi:10.1080/15476286.2017.1290041 · Cited by 69
Human eIF3: from ‘blobology’ to biological insight
Cate, J. H. D. (2017) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2016.0176 · Cited by 71
The androgen receptor regulates a druggable translational regulon in advanced prostate cancer
Liu, Y., Horn, J. L., Banda, K., Goodman, A. Z., Lim, Y., Jana, S., Arora, S., Germanos, A. A., Wen, L., Hardin, W. R., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw4993 · Cited by 68
Self-citation
The Role of Translation Control in Tumorigenesis and Its Therapeutic Implications
Xu, Y., & Ruggero, D. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033420 · Cited by 67
Self-citation
The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells
Brina, D., Ponzoni, A. A., Troiani, M., Calì, B., Pasquini, E., Attanasio, G., Mosole, S., Mirenda, M., D’Ambrosio, M., Colucci, M., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00594-z · Cited by 68
Evolutionarily divergent mTOR remodels translatome for tissue regeneration
Zhulyn, O., Rosenblatt, H. D., Shokat, L., Dai, S. A., Kuzuoğlu‐Öztürk, D., Zhang, Z., Ruggero, D., Shokat, K. M., & Barna, M. (2023) · Nature · doi:10.1038/s41586-023-06365-1 · Cited by 73
Self-citation
Revealing nascent proteomics in signaling pathways and cell differentiation
Forester, C. M., Zhao, Q. C., Phillips, N. J., Urisman, A., Chalkley, R. J., Osés-Prieto, J. A., Zhang, L., Ruggero, D., & Burlingame, A. L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707514115 · Cited by 68
Self-citation
Genome‐Wide Annotation and Quantitation of Translation by Ribosome Profiling
Ingolia, N. T., Brar, G. A., Rouskin, S., McGeachy, A. M., & Weissman, J. S. (2013) · Current Protocols in Molecular Biology · doi:10.1002/0471142727.mb0418s103 · Cited by 70
Self-citation
Ligation-free ribosome profiling of cell type-specific translation in the brain
Hornstein, N. J., Torres, D., Sharma, S. D., Tang, G., Canoll, P., & Sims, P. A. (2016) · Genome biology · doi:10.1186/s13059-016-1005-1 · Cited by 70
The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma
Miyahara, H., Yadavilli, S., Natsumeda, M., Rubens, J. A., Rodgers, L. T., Kambhampati, M., Taylor, I. C., Kaur, H., Asnaghi, L., Eberhart, C. G., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.04.019 · Cited by 66
Time-Resolved Proteomics Extends Ribosome Profiling-Based Measurements of Protein Synthesis Dynamics
Liu, T., Huang, H. H., Wheeler, D., Xu, Y., Wells, J. A., Song, Y. S., & Wiita, A. P. (2017) · Cell Systems · doi:10.1016/j.cels.2017.05.001 · Cited by 69
Annexins—Coordinators of Cholesterol Homeostasis in Endocytic Pathways
Rentero, C., Blanco‐Muñoz, P., Meneses‐Salas, E., Grewal, T., & Enrich, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051444 · Cited by 69
Concerted 2-5A-Mediated mRNA Decay and Transcription Reprogram Protein Synthesis in the dsRNA Response
Rath, S. P., Prangley, E., Donovan, J., Demarest, K., Wingreen, N. S., Meir, Y., & Korennykh, A. V. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.07.027 · Cited by 67
Rasgrp1 mutation increases naïve T-cell CD44 expression and drives mTOR-dependent accumulation of Helios+ T cells and autoantibodies
Daley, S. R., Coakley, K. M., Hu, D. Y., Randall, K. L., Jenne, C. N., Limnander, A., Myers, D. R., Polakos, N. K., Enders, A., Roots, C. M., et al. (2013) · eLife · doi:10.7554/elife.01020 · Cited by 67
PAT4 levels control amino-acid sensitivity of rapamycin-resistant mTORC1 from the Golgi and affect clinical outcome in colorectal cancer
Fan, S.-J., Snell, C. E., Turley, H., Li, J., McCormick, R. D., Perera, S., Heublein, S., Kazi, S., Azad, A. K., WILSON, C. G., et al. (2015) · Oncogene · doi:10.1038/onc.2015.363 · Cited by 69
Brain somatic mutations in MTOR reveal translational dysregulations underlying intractable focal epilepsy
Kim, J., Cho, J., Kim, S. H., Kang, H., Kim, D.-S., Kim, V. N., & Lee, J. H. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127032 · Cited by 67
mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review
Statz, C. M., Patterson, S. E., & Mockus, S. M. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0453-6 · Cited by 65
PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer
Chen, L., Jin, T., Zhu, K., Piao, Y., Quan, T., Quan, C., & Lin, Z. (2017) · Oncotarget · doi:10.18632/oncotarget.14442 · Cited by 64
Axon TRAP reveals learning-associated alterations in cortical axonal mRNAs in the lateral amygdala
Ostroff, L. E., Santini, E., Sears, R. M., Deane, Z., Kanadia, R., LeDoux, J. E., Lhakhang, T. W., Tsirigos, A., Heguy, A., & Klann, E. (2019) · eLife · doi:10.7554/elife.51607 · Cited by 68
A network of RNA-binding proteins controls translation efficiency to activate anaerobic metabolism
Ho, J. J. D., Balukoff, N. C., Theodoridis, P. R., Wang, M., Krieger, J. R., Schatz, J. H., & Lee, S. (2020) · Nature Communications · doi:10.1038/s41467-020-16504-1 · Cited by 66
Cross talk between autophagy and oncogenic signaling pathways and implications for cancer therapy
Zada, S., Hwang, J. S., Ahmed, M., Lai, T. H., Pham, T. M., Elashkar, O., & Kim, D. R. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188565 · Cited by 65
Distinct germline progenitor subsets defined through Tsc2–mTORC1 signaling
Hobbs, R. M., La, H. M., Mäkelä, J., Kobayashi, T., Noda, T., & Pandolfi, P. P. (2015) · EMBO Reports · doi:10.15252/embr.201439379 · Cited by 65
The Complex Roles of Mechanistic Target of Rapamycin in Adipocytes and Beyond
Lee, P. L., Jung, S. M., & Guertin, D. A. (2017) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2017.01.004 · Cited by 66
Oncogene-dependent sloppiness in mRNA translation
Champagne, J., Pataskar, A., Blommaert, N., Nagel, R., Wernaart, D., Ramalho, S., Kenski, J. C. N., Bleijerveld, O. B., Zaal, E. A., Berkers, C. R., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.09.002 · Cited by 64
GOLPH3 promotes glioblastoma cell migration and invasion via the mTOR‐YB1 pathway in vitro
Zhang, X., Ding, Z., Mo, J., Sang, B., Shi, Q., Hu, J., Xie, S. P., Zhan, W., Lu, D., Yang, M., et al. (2014) · Molecular Carcinogenesis · doi:10.1002/mc.22197 · Cited by 65
Hepatitis B Virus Pre-S2 Mutant Induces Aerobic Glycolysis through Mammalian Target of Rapamycin Signal Cascade
Teng, C., Hsieh, W.-C., Wu, H., Lin, Y.-J., Tsai, H.-W., Huang, W., & Su, I. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122373 · Cited by 63
Fragile X mental retardation protein: A paradigm for translational control by RNA-binding proteins
Chen, E., & Joseph, S. (2015) · Biochimie · doi:10.1016/j.biochi.2015.02.005 · Cited by 66
Evolutionarily conserved regulation of TOR signalling
Takahara, T., & Maeda, T. (2013) · The Journal of Biochemistry · doi:10.1093/jb/mvt047 · Cited by 64
Novel oncogene 5MP1 reprograms c-Myc translation initiation to drive malignant phenotypes in colorectal cancer
Sato, K., Masuda, T., Hu, Q., Tobo, T., Gillaspie, S., Niida, A., Thornton, M. M., Kuroda, Y., Eguchi, H., Nakagawa, T., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.05.058 · Cited by 64
Penetrating injuries to the thoracic great vessels.
Demetriades, D. (1997) · PubMed · Cited by 63
The next generation of PI3K-Akt-mTOR pathway inhibitors in breast cancer cohorts
McKenna, M., McGarrigle, S. A., & Pidgeon, G. P. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.08.001 · Cited by 64
Elevation of Receptor Tyrosine Kinases by Small Molecule AKT Inhibitors in Prostate Cancer Is Mediated by Pim-1
Cen, B., Mahajan, S., Wang, W., & Kraft, A. S. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4619 · Cited by 62
The impact of cow's milk-mediated mTORC1-signaling in the initiation and progression of prostate cancer
Melnik, B. C., John, S. M., Carrera‐Bastos, P., & Cordain, L. (2012) · Nutrition & Metabolism · doi:10.1186/1743-7075-9-74 · Cited by 63
The mTORC1-4E-BP-eIF4E axis controls de novo Bcl6 protein synthesis in T cells and systemic autoimmunity
Yi, W., Gupta, S. K., Ricker, E., Manni, M., Jessberger, R., Chinenov, Y. V., Molina, H., & Pernis, A. B. (2017) · Nature Communications · doi:10.1038/s41467-017-00348-3 · Cited by 64
Clinical development of mTOR inhibitors in breast cancer
Vicier, C., Dieci, M. V., Arnedos, M., Delaloge, S., Viens, P., & André, F. (2014) · Breast Cancer Research · doi:10.1186/bcr3618 · Cited by 61
Extra-virgin olive oil contains a metabolo-epigenetic inhibitor of cancer stem cells
Corominas-Faja, B., Cuyàs, E., Lozano‐Sánchez, J., Cufí, S., Verdura, S., Fernández‐Arroyo, S., Borrás‐Linares, I., Martı́n-Castillo, B., Martín, Á. G., Lupu, R., et al. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy023 · Cited by 61
Metabolic alterations in the tumor microenvironment and their role in oncogenesis
Eisenberg, L., Eisenberg‐Bord, M., Eisenberg‐Lerner, A., & Sagi‐Eisenberg, R. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.04.016 · Cited by 63
Upregulated YB-1 protein promotes glioblastoma growth through a YB-1/CCT4/mLST8/mTOR pathway
Wang, J.-Z., Zhu, H., You, P., Liu, H., Wang, W.-K., Fan, X., Yang, Y., Xu, K., Zhu, Y., Li, Q., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci146536 · Cited by 60
Remodelling of the translatome controls diet and its impact on tumorigenesis
Yang, H., Zingaro, V. A., Lincoff, J., Tom, H. J., Oikawa, S., Osés-Prieto, J. A., Edmondson, Q. D., Seiple, I. B., Shah, H., Kajimura, S., et al. (2024) · Nature · doi:10.1038/s41586-024-07781-7 · Cited by 63
Self-citation
The PI3K/Akt/mTOR Signaling Pathway in Triple-Negative Breast Cancer: A Resistance Pathway and a Prime Target for Targeted Therapies
Hassan, M. A., & Aubel, C. (2025) · Cancers · doi:10.3390/cancers17132232 · Cited by 60
Milk disrupts p53 and DNMT1, the guardians of the genome: implications for acne vulgaris and prostate cancer
Melnik, B. C. (2017) · Nutrition & Metabolism · doi:10.1186/s12986-017-0212-4 · Cited by 62

Authors: Hsieh, A. C., Liu, Y., Edlind, M. P., Ingolia, N. T., Janes, M. R., Sher, A., Shi, E. Y., Stumpf, C. R., Christensen, C., Bonham, M. J., Wang, S., Ren, P., Martin, M., Jessen, K., Feldman, M. E., Weissman, J. S., Shokat, K. M., Rommel, C., & Ruggero, D.
Affiliations: University of California, San Francisco (US)
Intel (United States) (US)
Carnegie Institution for Science (US)
Howard Hughes Medical Institute (US)
Corresponding author: Rommel, Christian
Ruggero, Davide
ORCID: Hsieh, Andrew C.
Liu, Yi
Ingolia, Nicholas T.
Janes, Matthew R.
Stumpf, Craig R.
Ren, Pingda
Weissman, Jonathan S.
Shokat, Kevan M.
Ruggero, Davide
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2012-02-22
Volume: 485
Issue: 7396
Pages: 55-61
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature10912
PMC: PMC3663483
OpenAlex: W1980396381
Cited by: 1,313
References: 40
Citations by year: 2026: 59 · 2025: 64 · 2024: 65 · 2023: 86 · 2022: 92 · 2021: 93 · 2020: 90 · 2019: 96 · 2018: 104 · 2017: 105 · 2016: 94 · 2015: 98 · 2014: 121 · 2013: 108 · 2012: 36
FWCI: 43.69
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: Howard Hughes Medical Institute
National Cancer Institute (R01CA140456, R01CA154916)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
Keywords: mTOR signaling, prostate cancer, metastasis, tumor invasion, translational regulation, ribosome profiling, 4E-BP1, mTORC1, INK128, oncogenic translation, cell proliferation, cancer metabolism
MeSH terms: Adenine, Animals, Benzoxazoles, Cell Movement, Humans, Male, Mice, Inbred C57BL, Neoplasm Invasiveness, Neoplasm Metastasis, Phosphoproteins, Prostatic Neoplasms, Pyrimidines, Repressor Proteins, RNA, Messenger, Protein Biosynthesis, Signal Transduction, Gene Expression Regulation, Neoplastic, Genome, Cell Cycle Proteins, Eukaryotic Initiation Factor-4E, Eukaryotic Initiation Factors, Cell Line, Tumor, Adaptor Proteins, Signal Transducing, Mice, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The translational landscape of mTOR signalling steers cancer initiation and metastasis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks